Paper33933552
The dual roles of A20 in cancer.
Shi Y and 5 others. Cancer Lett, 2021. Cited by 35 papers, by iCite.
Cite this record
ConductScience Library. The dual roles of A20 in cancer. Papers, record 33933552. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33933552
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics5
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Neoplasms | Major topic |
| Tumor Necrosis Factor alpha-Induced Protein 3 | Major topic |
| Animals | |
| Humans | |
| Mice |
Source PubMed
Cited by29
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 35 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42844863 | A20 Inhibits IFN-γ Signaling in Hepatocellular Carcinoma Cells by Binding to STAT1, Compromising Anti-Tumor Immunity. | Cancer Sci | 2026 | https://conductscience.org/library/papers/42844863 | PubMed |
| 42704536 | The ubiquitin-editing enzyme A20 (TNFAIP3): mechanisms of activation, biological function, diseases and therapeutic targets. | Mol Biomed | 2026 | https://conductscience.org/library/papers/42704536 | PubMed |
| 42279358 | Comprehensive Analysis of Genomic and Phenomic Data Reveals Context-Dependent Function of A20 (TNFAIP3) in Renal Cell Carcinoma. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42279358 | PubMed |
| 42095873 | Exosomal miR-27a-3p promotes osteosarcoma lung metastasis by negatively regulating TNFAIP3 to form a premetastatic niche. | Mol Genet Genomics | 2026 | https://conductscience.org/library/papers/42095873 | PubMed |
| 41405367 | A20 Facilitates Oxaliplatin Sensitivity in Colorectal Cancer Through Monoubiquitylation of IKK-β. | Adv Sci (Weinh) | 2026 | https://conductscience.org/library/papers/41405367 | PubMed |
| 40644541 | Transition of cellular senescence to pyroptosis mediates recurrence of small cell lung cancer after chemotherapy. | Sci Adv | 2025 | https://conductscience.org/library/papers/40644541 | PubMed |
| 40214497 | The Role of A20 in Cancer: Friend or Foe? | Cells | 2025 | https://conductscience.org/library/papers/40214497 | PubMed |
| 40146279 | February In focus in HCB. | Histochem Cell Biol | 2025 | https://conductscience.org/library/papers/40146279 | PubMed |
| 40098908 | Tubeimoside I Inhibits the Proliferation of Liver Cancer Through Inactivating NF-κB Pathway by Regulating TNFAIP3 Expression. | Drug Des Devel Ther | 2025 | https://conductscience.org/library/papers/40098908 | PubMed |
| 39738689 | Differential expression of the ubiquitin-editing enzyme A20 in gastric biopsies indicates the severity of disease. | Histochem Cell Biol | 2024 | https://conductscience.org/library/papers/39738689 | PubMed |
| 39724264 | ZSH-2208: A novel retinoid with potent anti-tumour effects on ESCC stem cells via RARγ-TNFAIP3 axis. | Clin Transl Med | 2025 | https://conductscience.org/library/papers/39724264 | PubMed |
| 39678489 | Deubiquitinases as novel therapeutic targets for diseases. | MedComm (2020) | 2024 | https://conductscience.org/library/papers/39678489 | PubMed |
| 39094893 | The molecular mechanism of NF-κB dysregulation across different subtypes of renal cell carcinoma. | J Adv Res | 2025 | https://conductscience.org/library/papers/39094893 | PubMed |
| 39028490 | Molecular profiling of core immune-escape genes highlights TNFAIP3 as an immune-related prognostic biomarker in neuroblastoma. | Inflamm Res | 2024 | https://conductscience.org/library/papers/39028490 | PubMed |
| 38928333 | A20 in Kidney Transplantation and Autoimmunity. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/38928333 | PubMed |
| 38577591 | ASB6 as an Independent Prognostic Biomarker for Colorectal Cancer Progression Involves Lymphatic Invasion and Immune Infiltration. | J Cancer | 2024 | https://conductscience.org/library/papers/38577591 | PubMed |
| 38573314 | Identification of potential drug targets for allergic diseases from a genetic perspective: A mendelian randomization study. | Clin Transl Allergy | 2024 | https://conductscience.org/library/papers/38573314 | PubMed |
| 38451381 | The Complexity of Being A20: From Biological Functions to Genetic Associations. | J Clin Immunol | 2024 | https://conductscience.org/library/papers/38451381 | PubMed |
| 38322025 | Integrated transcriptome and cell phenotype analysis suggest involvement of PARP1 cleavage, Hippo/Wnt, TGF-β and MAPK signaling pathways in ovarian cancer cells response to cannabis and PARP1 inhibitor treatment. | Front Genet | 2024 | https://conductscience.org/library/papers/38322025 | PubMed |
| 38192819 | N6-methyladenosine methylation in ophthalmic diseases: From mechanisms to potential applications. | Heliyon | 2024 | https://conductscience.org/library/papers/38192819 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| IGKV1-27 | 28935 | PubTator's text mining | https://conductscience.org/library/genes/28935 | NCBI Gene |
| TNFAIP3 | 7128 | PubTator's text mining | https://conductscience.org/library/genes/7128 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/33933552
GET https://conductscience.org/api/papers/v1/33933552/cited_by?page=2